ISTH 2025 for Cardiac Surgery: LEX-211 (FARES-II) Trial Shows Promising Results
The International Society on Thrombosis and Haemostasis (ISTH) shared a post on X:
”New science from ISTH 2025! Watch this expert interview to learn about groundbreaking findings from the LEX-211 (FARES-II) trial on cardiac surgery.
Key takeaways:
- Superior efficacy
- Reduced transfusions
- Fewer serious adverse events”
To watch the full interview, follow the link.
Big news for cardiac surgery is coming from ISTH!
New data presented at ISTH 2025 from the LEX-211 (FARES-II) trial highlight significant advances in hemostatic management during cardiac surgery.
The trial demonstrated superior efficacy of LEX-211, with reduced transfusion requirements and fewer serious adverse events compared to standard care.
These findings mark a potential breakthrough in improving perioperative outcomes and patient safety in cardiac surgery.
Stay updated on the World of Thrombosis and Bleeding with Hemostasis Today.
-
Apr 15, 2026, 04:52Ulrich Pecks: Personalized Approaches to VTE Prevention in Pregnant Women with Inherited Thrombophilia
-
Apr 15, 2026, 04:06Brenda Pleasant: Insights from the HFA Symposium on Hemophilia Care
-
Apr 15, 2026, 03:43Lexy Halloran: Addressing Diagnostic Inequities in Women with Chronic Conditions
-
Apr 14, 2026, 17:32Denise M.: Surviving Sepsis 2026 – The Upstream Revolution
-
Apr 14, 2026, 17:23Meghanath Yenni։ What’s New in Acute Ischemic Stroke in 2026
-
Apr 14, 2026, 17:11Phil Spinella: What Dose of TXA for Children With Severe Traumatic Bleeding Should You Use?
-
Apr 14, 2026, 17:08Abdulrahman Katib: How Endovascular Stenting Is Transforming the Treatment of Severe PTS
-
Apr 14, 2026, 17:00Anna A. Avagyan: Glad to Be Part of EHA Pediatric Hematology-Oncology Course
-
Apr 14, 2026, 16:58Ney Carter Borges: NLRP3 Inhibition in Atherosclerosis – Early Clinical Signal Beyond Lipids